This guideline included an introduction to the assessment and treatment of delirium and drug-specific recommendations for various time frames and clinical situations.
This guideline includes a massive transfusion protocol (MTP), which is activated by the patient's attending physician (anaesthesiologist, intensivist, surgeon or emergency physician).
This guideline included a recommendation that sponsors perform a meta-analysis of the important CV events across phase 2 and phase 3 controlled clinical trials, and explore similarities and/or differences in subgroups (eg, age, sex, race), if possible.
Key changes encompassed in this version of the guideline include new recommendations on coagulation support and monitoring and the appropriate use of local haemostatic measures, tourniquets, calcium and desmopressin in the bleeding trauma patient.
Key changes encompassed in this version of the guideline include new recommendations on the appropriate use of vasopressors and inotropic agents, and reflect an awareness of the growing number of patients in the population at large treated with antiplatelet agents and/or oral anticoagulants.
The key revisions in this updated guideline include changed recommendations for regimens for antibiotic prophylaxis, susceptibility testing, and management of women with pre-labour rupture of membranes.
This version of the guideline includes a new section on the appropriate use of vasopressors and inotropic agents and reflects an awareness of the growing number of patients in the population at large treated with antiplatelet agents and/or oral anticoagulants.
Those agreeing to the guidelines include BP Amoco, Chevron, Freeport McMoRan Copper & Gold, Conoco, Shell and Texaco, along with Amnesty International, Human Rights Watch and other rights groups.
Development of this PTSD Guideline included a systematic assessment of eight randomised controlled trials (RCTs) involving children with substantiated contact sexual abuse [ 11- 19].
